Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 352

1.

Efficacy of depot leuprolide in premenstrual syndrome: effect of symptom severity and type in a controlled trial.

Brown CS, Ling FW, Andersen RN, Farmer RG, Arheart KL.

Obstet Gynecol. 1994 Nov;84(5):779-86.

PMID:
7936512
2.

Gonadotropin-releasing hormone agonist in treatment of premenstrual symptoms with and without comorbidity of depression: a pilot study.

Freeman EW, Sondheimer SJ, Rickels K, Albert J.

J Clin Psychiatry. 1993 May;54(5):192-5.

PMID:
8509350
3.
4.

Depot leuprolide acetate with estrogen and progestin add-back for long-term treatment of premenstrual syndrome.

Mezrow G, Shoupe D, Spicer D, Lobo R, Leung B, Pike M.

Fertil Steril. 1994 Nov;62(5):932-7.

PMID:
7926137
5.

Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome.

Schmidt PJ, Nieman LK, Danaceau MA, Adams LF, Rubinow DR.

N Engl J Med. 1998 Jan 22;338(4):209-16.

6.

Premenstrual syndrome and related hormonal changes. Long-acting gonadotropin releasing hormone agonist treatment.

Helvacioglu A, Yeoman RR, Hazelton JM, Aksel S.

J Reprod Med. 1993 Nov;38(11):864-70.

PMID:
8277482
7.

Use of leuprolide acetate plus tibolone in the treatment of severe premenstrual syndrome.

Di Carlo C, Palomba S, Tommaselli GA, Guida M, Di Spiezio Sardo A, Nappi C.

Fertil Steril. 2001 Feb;75(2):380-4.

PMID:
11172843
8.

Treatment of premenstrual syndrome with gonadotropin-releasing hormone agonist in a low dose regimen.

Sundström I, Nyberg S, Bixo M, Hammarbäck S, Bäckström T.

Acta Obstet Gynecol Scand. 1999 Nov;78(10):891-9.

PMID:
10577620
9.

Efficacy of progesterone vaginal suppositories in alleviation of nervous symptoms in patients with premenstrual syndrome.

Baker ER, Best RG, Manfredi RL, Demers LM, Wolf GC.

J Assist Reprod Genet. 1995 Mar;12(3):205-9.

PMID:
8520187
10.

Evaluation of different add-back estradiol and progesterone treatments to gonadotropin-releasing hormone agonist treatment in patients with premenstrual dysphoric disorder.

Segebladh B, Borgström A, Nyberg S, Bixo M, Sundström-Poromaa I.

Am J Obstet Gynecol. 2009 Aug;201(2):139.e1-8. doi: 10.1016/j.ajog.2009.03.016.

PMID:
19398092
11.

Effect of leuprolide acetate in patients with moderate to severe functional bowel disease. Double-blind, placebo-controlled study.

Mathias JR, Clench MH, Reeves-Darby VG, Fox LM, Hsu PH, Roberts PH, Smith LL, Stiglich NJ.

Dig Dis Sci. 1994 Jun;39(6):1155-62.

PMID:
8200247
12.

Pyridoxine (vitamin B6) and the premenstrual syndrome: a randomized crossover trial.

Doll H, Brown S, Thurston A, Vessey M.

J R Coll Gen Pract. 1989 Sep;39(326):364-8.

14.

The efficacy of Femal in women with premenstrual syndrome: a randomised, double-blind, parallel-group, placebo-controlled, multicentre study.

Gerhardsen G, Hansen AV, Killi M, Fornitz GG, Pedersen F, Roos SB.

Adv Ther. 2008 Jun;25(6):595-607. doi: 10.1007/s12325-008-0072-4.

PMID:
18568441
15.

Luteal phase sertraline treatment for premenstrual dysphoric disorder. Results of a double-blind, placebo-controlled, crossover study.

Jermain DM, Preece CK, Sykes RL, Kuehl TJ, Sulak PJ.

Arch Fam Med. 1999 Jul-Aug;8(4):328-32.

PMID:
10418540
16.

A randomized, placebo-controlled, crossover trial of danazol for the treatment of premenstrual syndrome.

Hahn PM, Van Vugt DA, Reid RL.

Psychoneuroendocrinology. 1995;20(2):193-209.

PMID:
7899538
17.

Differential response to antidepressants in women with premenstrual syndrome/premenstrual dysphoric disorder: a randomized controlled trial.

Freeman EW, Rickels K, Sondheimer SJ, Polansky M.

Arch Gen Psychiatry. 1999 Oct;56(10):932-9.

PMID:
10530636
18.

Treatment of premenstrual syndrome with fluoxetine: a double-blind, placebo-controlled, crossover study.

Wood SH, Mortola JF, Chan YF, Moossazadeh F, Yen SS.

Obstet Gynecol. 1992 Sep;80(3 Pt 1):339-44.

PMID:
1495689
19.

Crocus sativus L. (saffron) in the treatment of premenstrual syndrome: a double-blind, randomised and placebo-controlled trial.

Agha-Hosseini M, Kashani L, Aleyaseen A, Ghoreishi A, Rahmanpour H, Zarrinara AR, Akhondzadeh S.

BJOG. 2008 Mar;115(4):515-9. doi: 10.1111/j.1471-0528.2007.01652.x.

20.

A preliminary study of luteal phase versus symptom-onset dosing with escitalopram for premenstrual dysphoric disorder.

Freeman EW, Sondheimer SJ, Sammel MD, Ferdousi T, Lin H.

J Clin Psychiatry. 2005 Jun;66(6):769-73.

PMID:
15960573

Supplemental Content

Support Center